Close Menu

NEW YORK (GenomeWeb) – Fred Hutchinson Cancer Research Center spinout Adaptive Biotechnologies has acquired immune sequencing company Sequenta, the companies said today.

Adaptive Biotechnologies CEO Chad Robins will remain as CEO of the combined company. Tom Willis, Sequenta co-founder and CEO, and Malek Faham, co-founder and chief scientific officer of Sequenta, will join the senior leadership team and report to Robins. Willis and John Stuelpnagel, Sequenta's chairman, will join the board of directors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.